Industry News

New AI Method Predicts Breast Cancer Five Years in Advance

By Medimaging International staff writers
18 May 2019

Image: A new AI method for detecting breast cancer is expected to surpass existing methods that fall short in their predictions (Photo courtesy of MIT).Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to predict a woman’s future risk of breast cancer. The currently available models that use factors such as family history and genetics fall far short in predicting an individual woman’s likelihood of being diagnosed with breast cancer.

In some models, breast density—the amount of dense tissue compared to the amount of fatty tissue in the breast on a mammogram— has been added to improve risk assessment as it is an independent risk factor for breast cancer. Since it is based on subjective assessment that can vary across radiologists, deep learning, a subset of AI in which computers learn by example, has been studied as a way to standardize and automate these measurements.

Adam Yala, a Ph.D. candidate at the Massachusetts Institute of Technology (MIT), in collaboration with Regina Barzilay, Ph.D., an AI expert and professor at MIT, and Constance Lehman, M.D, Ph.D., chief of breast imaging at Massachusetts General Hospital and professor of radiology at Harvard Medical School, recently compared three different risk assessment approaches.

The first model relied on traditional risk factors, the second on deep learning that used the mammogram alone, and the third on a hybrid approach that incorporated both the mammogram and traditional risk factors into the deep learning model. The researchers used nearly 90,000 full-resolution screening mammograms from about 40,000 women to train, validate and test the deep learning model. They were able to obtain cancer outcomes through linkage to a regional tumor registry.

The deep learning models yielded substantially improved risk discrimination over the Tyrer-Cuzick model, a current clinical standard that uses breast density in factoring risk. When comparing the hybrid deep learning model against breast density, the researchers found that patients with non-dense breasts and model-assessed high risk had 3.9 times the cancer incidence of patients with dense breasts and model-assessed low risk. The advantages held across different subgroups of women.

“There’s much more information in a mammogram than just the four categories of breast density. By using the deep learning model, we learn subtle cues that are indicative of future cancer,” said Yala. “There’s a very large amount of information in a full-resolution mammogram that breast cancer risk models have not been able to use until recently. Using deep learning, we can learn to leverage that information directly from the data and create models that are significantly more accurate across diverse populations.”

“Unlike traditional models, our deep learning model performs equally well across diverse races, ages and family histories,” Dr. Barzilay said. “Until now, African-American women were at a distinct disadvantage in having accurate risk assessment of future breast cancer. Our AI model has changed that.”

“A missing element to support more effective, more personalized screening programs has been risk-assessment tools that are easy to implement and that work across the full diversity of women whom we serve,” Dr. Lehman said. “We are thrilled with our results and eager to work closely with our health care systems, our providers and, most importantly, our patients to incorporate this discovery into improved outcomes for all women.”

Related Links:
MIT



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

12 Sep 2019
ERBA Mannheim Opens New Subsidiary in Brazil
ERBA Mannheim has expanded its global footprint by opening a new subsidiary in Brazil.
Read More
10 Sep 2019
Imaging Informatics Summit Highlights Impact of AI Technologies on Patient Care
The 2019 Imaging Informatics Summit organized by the American College of Radiology will be held in Washington, D.C., USA, on October 5–6, 2019, and will focus on the role that artificial intelligence (AI) and data can play in improving patient care.
Read More
10 Sep 2019
ZOLL Medical Completes Acquisition of Cardiac Science
ZOLL Medical Corporation, which manufactures medical devices and related software solutions, has completed the previously announced acquisition of Cardiac Science Corporation, a provider of automated external defibrillators (AEDs), related services, and accessories.
Read More
10 Sep 2019
Growing Inclination Towards Handheld Ultrasound Scanners for POC Diagnostics
The global handheld ultrasound scanners market was valued at USD 62.2 million in 2017 and is projected to grow at a CAGR of 17% during the forecast period 2018-2026, driven primarily by their increasingly popularity among clinicians across the world for point-of-care diagnosis.
Read More
10 Sep 2019
AI-Enabled Technology to Help Global Molecular Imaging Market Reach USD 11.13 Billion by 2028
The global molecular imaging market was estimated at USD 6.84 billion in 2018 and is projected to grow at a CAGR of 5.03% during the forecast period 2019-2028 to reach USD 11.13 billion by 2028.
Read More
10 Sep 2019
DiA and Edan Instruments Collaborate to Offer AI-Based Cardiac Ultrasound Solutions
DiA Imaging Analysis Ltd., a provider of artificial intelligence (AI)-powered ultrasound analysis solutions, has entered into a partnership with Edan Instruments Inc, a medical products and services company, to offer DiA's AI-based cardiac analysis solutions as an integrated part of Edan's ultrasound devices.
Read More
29 Aug 2019
Machine-Learning Algorithm Diagnoses Cancer Early and Accurately
A team of researchers from the University of Southern California used synthetic images to train a machine-learning algorithm that can assist in more quickly and correctly detecting breast cancer.
Read More
29 Aug 2019
Researchers Develop World’s First AI-Augmented Ova and Parasite Detection Tool
ARUP Laboratories, a national reference laboratory engaged in innovative laboratory research and development, and Techcyte, a developer of artificial intelligence (AI) based image analysis solutions for the diagnostics industry, have developed the world’s first AI-augmented ova and parasite detection tool.
Read More
29 Aug 2019
Global Immunoassay Market to Reach USD 19.76 Billion by 2025 with Increased Use in Oncology
The global immunoassay market is projected to grow at a CAGR of 5.9% from 2019 to reach USD 19.76 billion by 2025, driven by increasing incidences of chronic and infectious diseases, growing use of immunoassay in oncology, rise in drug and alcohol testing, and technological advancements in immunoassay.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions